GeoVax Labs, Inc. Share Price
NASDAQ: GOVX | Micro CapGeoVax Labs, Inc. Stock Performance
Open $0.78 | Prev. Close $0.76 | Circuit Range N/A |
Day Range $0.78 - $0.78 | Year Range $0.12 - $4.36 | Volume 1,195 |
Average Traded $0.78 |
GeoVax Labs, Inc. Share Price Today
As of 10 August 2026, GeoVax Labs, Inc.'s share price is $0.77. The stock opened at $0.78, compared to its previous close of $0.76. During today's trading session, GeoVax Labs, Inc.'s share price traded between $0.78 and $0.78, with an average price of $0.78. Over the past 52 weeks, the stock has recorded a high of $4.36 and a low of $0.12. In terms of performance, GeoVax Labs, Inc.'s share price has declined by 52.56% over the last six months and is up 4.27% on a year-on-year basis.
GeoVax Labs, Inc. Share Price Chart
GeoVax Labs, Inc. Stock Fundamentals & Key Indicators
Market Cap $736563.45 | PE Ratio (TTM) -0.03 | Dividend Yield N/A |
EPS (TTM) $-22.40 | Revenue (TTM) $2.49M | Return On Equity (TTM) -561.15% |
Profit Margin -862.34% | Debt to Equity 0.51 | Quarterly Earnings Growth YoY -8.66% |
GeoVax Labs, Inc. Quarterly Profit & Loss
All figures in USD
GeoVax Labs, Inc. Annual Profit & Loss
All figures in USD
About GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
GeoVax Labs, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.73 | $0.78 | +9.26% |
Jul 2026 | $1.27 | $0.71 | -42.96% |
Jun 2026 | $2.27 | $1.25 | -40.76% |
May 2026 | $1.14 | $2.11 | +114.65% |
Apr 2026 | $1.39 | $0.98 | -26.09% |
Mar 2026 | $1.60 | $1.33 | -17.90% |
Feb 2026 | $2.74 | $1.62 | -42.04% |
Jan 2026 | $0.18 | $2.79 | +1,497.14% |
Dec 2025 | $0.41 | $0.17 | -57.42% |
Nov 2025 | $0.56 | $0.41 | -25.81% |
Oct 2025 | $0.49 | $0.55 | +17.87% |
Sep 2025 | $0.73 | $0.47 | -36.23% |
GOVX Share Price FAQs
What is GeoVax Labs, Inc. share price today?
What is the 52 week high and 52 week low of GeoVax Labs, Inc. stock?
What is GOVX's market capitalisation today?
What is GOVX's net income for the last quarter?
What is the 5 year returns of GOVX?
What is the high & low stock price of GOVX today?
Can I buy GOVX shares in India?